Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population

被引:220
作者
Yasar, Ü
Eliasson, E
Dahl, ML
Johansson, I
Ingelman-Sundberg, M
Sjoqvist, F
机构
[1] Karolinska Inst, Div Mol Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Div Clin Pharmacol, Dept Med Sci & Technol, S-14186 Huddinge, Sweden
关键词
polymorphism; genotyping; CYP2C9; warfarin; NSAID;
D O I
10.1006/bbrc.1998.9992
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytochrome P450 2C9 (CYP2C9) catalysis the metabolism of important drugs such as phenytoin, S-warfarin, tolbutamide, losartan, torasemide, and nonsteroidal anti-inflammatory drugs, A functional polymorphism of the CYP2C9 gene has been described. The variant alleles include CYP2C9*2 having a point mutation in exon 3 causing an Arg144Cys exchange, and CYP2C9*3 with a point mutation in exon 7 resulting in an Ile359Leu exchange. Genotyping of these variant forms was carried out in 430 Swedish healthy volunteers and three different methods were compared. Sequence analysis of the different PCR products revealed that other genes in the CYP2C locus were co-amplified in one of the methods applied, whereas the other two methods were specific for CYP2C9. The frequencies of the CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles in the population examined were found to be 0.819, 0.107, and 0.074, respectively. The need for careful evaluation of the genotyping procedure by sequence analysis of PCR products is emphasised, (C) 1999 Academic Press.
引用
收藏
页码:628 / 631
页数:4
相关论文
共 26 条
[1]  
ACKERMANN E, 1995, EUR J CLIN PHARMACOL, V52, pA71
[2]  
AITHAL GP, 1998, IN PRESS LANCET
[3]  
BERTILSSON L, 1995, ADV DRUG METABOLISM, P85
[4]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[5]   Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy [J].
Furuya, H ;
FernandezSalguero, P ;
Gregory, W ;
Taber, H ;
Steward, A ;
Gonzalez, FJ ;
Idle, JR .
PHARMACOGENETICS, 1995, 5 (06) :389-392
[6]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[7]   Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C [J].
Hamman, MA ;
Thompson, GA ;
Hall, SD .
BIOCHEMICAL PHARMACOLOGY, 1997, 54 (01) :33-41
[8]  
KAMINSKY LS, 1993, MOL PHARMACOL, V43, P234
[9]   THE SUBSTRATE-BINDING SITE OF HUMAN LIVER CYTOCHROME-P450 2C9 - AN APPROACH USING DESIGNED TIENILIC ACID-DERIVATIVES AND MOLECULAR MODELING [J].
MANCY, A ;
BROTO, P ;
DIJOLS, S ;
DANSETTE, PM ;
MANSUY, D .
BIOCHEMISTRY, 1995, 34 (33) :10365-10375
[10]  
MINERS JO, 1995, J PHARMACOL EXP THER, V272, P1076